Dyne Spends $161.7 Million On Research As It Prepares For A Potential Drug Launch
The quarterly loss widened to $193.6 million, with manufacturing, late-stage trials and launch preparations driving higher costs.
Dyne Therapeutics, which develops medicines for genetically driven neuromuscular diseases, spent $161.7 million on research in the third quarter, up from $97.2 million a year earlier, as manufacturing and late-stage trials pushed costs higher. Thursday’s earnings release, accompanying an SEC filing, also showed rising costs to prepare for a potential U.S. launch of its Duchenne muscular dystrophy treatment.
Manufacturing And Trials Lift Costs
Dyne’s third-quarter net loss was $193.6 million, compared with $108.0 million a year earlier. The loss per share widened to $1.06 from $0.76.
Research costs rose primarily because Dyne increased manufacturing of z-rostudirsen and spent more on the late-stage FORZETTO and HARMONIA trials. Administrative expenses reached $35.3 million, versus $16.7 million a year earlier, chiefly because of launch preparations, including hiring.
John Cox, Dyne’s president and chief executive officer, said the company was investing across multiple programs to realize the potential of its FORCE platform as it prepared for possible commercialization.
Cash, cash equivalents and marketable securities totaled $1.134 billion as of September 30, 2026. Dyne expects those resources to fund operations into the second quarter of 2028.
Duchenne Decision Comes In January
Z-rostudirsen’s FDA approval application is under priority review for Duchenne patients whose mutations are amenable to skipping exon 51. The FDA’s target decision date is January 21, 2027; Dyne continues to expect a potential U.S. launch in the first quarter of 2027 if approval arrives on the anticipated schedule.
The ongoing FORZETTO trial is designed to support traditional U.S. approval if accelerated approval is granted, as well as applications outside the U.S.
Dyne also presented preclinical findings at the Annual Neuromuscular Study Group Scientific Meeting supporting four Duchenne candidates. DYNE-244, DYNE-245, DYNE-253 and DYNE-255 target mutations amenable to skipping exons 44, 45, 53 and 55, respectively.
Dyne has no approved products yet. Its FORCE platform pairs an antibody fragment that binds the TfR1 receptor with a therapeutic payload, aiming to deliver treatment to muscle and the central nervous system. Its development portfolio also includes facioscapulohumeral muscular dystrophy and Pompe disease, and it holds global commercial rights to all its programs.
Myotonic Dystrophy Readout Next Year
For z-basivarsen, Dyne reported functional improvement across multiple measures at 12 months in pooled-dose participants in its early-to-mid-stage myotonic dystrophy type 1 trial. The comparisons covered participants’ starting measurements, placebo and a matched natural-history group.
The additional one-year results were presented at the Annual International Congress of the World Muscle Society and the American Association of Neuromuscular & Electrodiagnostic Medicine’s 2026 meeting. Dyne said the findings continued to support improvement in video-measured hand-opening time at six months as an early marker of clinical benefit.
Dyne plans results from the trial’s expansion group in the first quarter of 2027 to support a potential accelerated-approval application in the third quarter of 2027. That application would also draw on already-enrolled participants and the ongoing long-term extension.
The company expects a potential U.S. launch in the first half of 2028, conditional on priority review and timely FDA approval. Its ongoing late-stage HARMONIA trial is intended to support conversion to traditional approval, if accelerated approval is granted, and marketing applications outside the U.S.
The nearest regulatory milestone is the January 21, 2027 decision target for z-rostudirsen. Approval on Dyne’s anticipated schedule would allow its planned first-quarter U.S. launch.
Sources
- 8-K Filing — Dyne Therapeutics, Inc. (DYN) — SEC EDGAR
- Exhibit dyn-ex99_1.htm — Dyne Therapeutics, Inc. 8-K exhibit — SEC EDGAR
- Sarepta’s new CEO confident in clinical execution as DMD competitors close in - BioSpace — biospace.com
- Dyne Therapeutics Reports Third Quarter 2026 Financial — globenewswire.com